

# Jie Yu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3293789/publications.pdf>

Version: 2024-02-01

25  
papers

653  
citations

840776

11  
h-index

642732

23  
g-index

25  
all docs

25  
docs citations

25  
times ranked

1039  
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Positive Airway Pressure With Cardiovascular Events and Death in Adults With Sleep Apnea. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 156.	7.4	287
2	Homocysteine impairs coronary artery endothelial function by inhibiting tetrahydrobiopterin in patients with hyperhomocysteinemia. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2010, 299, E1061-E1065.	3.5	55
3	Peroxisome proliferator-activated receptor $\beta$ agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease. <i>Metabolism: Clinical and Experimental</i> , 2007, 56, 1396-1401.	3.4	43
4	High level of source-specific particulate matter air pollution associated with cardiac arrhythmias. <i>Science of the Total Environment</i> , 2019, 657, 1285-1293.	8.0	41
5	Effects of a reduced-sodium added-potassium salt substitute on blood pressure in rural Indian hypertensive patients: a randomized, double-blind, controlled trial. <i>American Journal of Clinical Nutrition</i> , 2021, 114, 185-193.	4.7	36
6	Resuming anticoagulants after anticoagulation-associated intracranial haemorrhage: systematic review and meta-analysis. <i>BMJ Open</i> , 2018, 8, e019672.	1.9	34
7	Interim effects of salt substitution on urinary electrolytes and blood pressure in the China Salt Substitute and Stroke Study (SSaSS). <i>American Heart Journal</i> , 2020, 221, 136-145.	2.7	20
8	Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program. <i>ESC Heart Failure</i> , 2021, 8, 1482-1493.	3.1	16
9	Coronary Flow Velocity Reserve is Improved by PPAR $\alpha$ Agonist Fenofibrate in Patients with Hypertriglyceridemia. <i>Cardiovascular Therapeutics</i> , 2013, 31, 161-167.	2.5	14
10	Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial. <i>Cardiovascular Research</i> , 2022, 118, 1103-1114.	3.8	13
11	Cost-Effectiveness of a Household Salt Substitution Intervention: Findings From 20 995 Participants of the Salt Substitute and Stroke Study. <i>Circulation</i> , 2022, 145, 1534-1541.	1.6	13
12	Sodium-glucose cotransporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 252-257.	4.4	12
13	Rationale, design, and baseline characteristics of the Salt Substitute in India Study (SSiS): The protocol for a double-blind, randomized-controlled trial. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1504-1512.	2.0	11
14	Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1927-1938.	4.4	10
15	Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 361-373.	4.5	9
16	Association between plasma ADAMTS-7 levels and severity of disease in patients with stable obstructive coronary artery disease. <i>Medicine (United States)</i> , 2016, 95, e5523.	1.0	8
17	The Role of Sodium Glucose Cotransporter-2 Inhibitors in Atherosclerotic Cardiovascular Disease: A Narrative Review of Potential Mechanisms. <i>Cells</i> , 2021, 10, 2699.	4.1	7
18	Optimal Time of Collapse to Return of Spontaneous Circulation to Apply Targeted Temperature Management for Cardiac Arrest: A Bayesian Network Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 784917.	2.4	7

#	ARTICLE	IF	CITATIONS
19	An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials. <i>International Journal of Cardiology</i> , 2021, 324, 165-172.	1.7	6
20	Heart Failure Therapies for the Prevention of HER2-Monoclonal Antibody-Mediated Cardiotoxicity: A Systematic Review and Meta-Analysis of Randomized Trials. <i>Cancers</i> , 2021, 13, 5527.	3.7	4
21	Antidiabetic Rosiglitazone Reduces Soluble Intercellular Adhesion Molecule-1 Level in Type 2 Diabetic Patients with Coronary Artery Disease. <i>PPAR Research</i> , 2008, 2008, 1-7.	2.4	3
22	Feasibility and validity of using death surveillance data and SmartVA for fact and cause of death in clinical trials in rural China: a substudy of the China salt substitute and stroke study (SSaSS). <i>Journal of Epidemiology and Community Health</i> , 2021, 75, 540-549.	3.7	2
23	Why Are We Forgetting Patients With Peripheral Arterial Disease?. <i>Heart Lung and Circulation</i> , 2021, 30, 939-942.	0.4	1
24	Protocol for the economic evaluation of the China Salt Substitute and Stroke Study (SSaSS). <i>BMJ Open</i> , 2021, 11, e045929.	1.9	1
25	Association of Baseline Diuretic Use With Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction: A Secondary Analysis From TOPCAT. <i>Journal of Cardiac Failure</i> , 2021, 27, 816-818.	1.7	0